• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Saturday 04/21/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

drug delivery

  • 1:02 PM

    Discusses Potential Role of New Cosmetic Botox Injection Technology in Dental Practices LIVINGSTON, NJ — MLSS, (Marketwired) — 12/12/17 — Milestone Scientific Inc . (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it participated in the 2017 Greater New York Dental Meeting (GNYDM), which was held November 26-29, 2017 in New York City. The GNYDM is the largest and most popular Dental Meeting, Exposition and Congress in the United States. The conference had over

    Read more
  • 12:02 PM

    Reflects expanding health and medical media coverage of Milestone’s technologies LIVINGSTON, NJ — MLSS, (Marketwired) — 11/28/17 — Milestone Scientific Inc . (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Wand® STA Dental and CompuFlo® Epidural systems were featured in separate television news broadcasts in Pittsburgh and South Florida, respectively. In addition, news of the commercial launch of the newly developed cosmetic instrument for delivery of botulinum toxin (such as

    Read more
  • 11:39 AM

    Results of In Vivo Study Signifies Completion of another Critical Milestone in Company’s Phase I of NIAID Contract* to Develop ODS Strip for Anti-Tuberculosis Treatment Option OXNARD, Calif., Oct. 03, 2017, CURR, (GLOBE NEWSWIRE) — Oak Therapeutics, a subsidiary of CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, has completed an in vivo study that compared the pharmacokinetics of its proprietary 300mg Isoniazid (INH) oral dissolvable strip (ODS) as an anti-tuberculosis (TB) treatment option against an existing

    Read more
  • 1:36 PM

    Significant Milestone Marks The Next Major Step in Beginning Phase 2 Trials in Cancer Using The Folate Receptor Alpha Peptide Vaccine Technology – – – – SEATTLE, Wash., Aug. 18, 2015, OTCQB, TPIV, /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV),  a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application)  to TapImmune as part of the recently completed licensing

    Read more
  • 1:23 PM

    Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials SEATTLE, July 27, 2015, TPIV, OTCQB, /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the

    Read more
  • 2:29 AM

    ELRA NNAN & PSSS More Info @ Web Site: www.OTCMarkets.com Tuesday, October 28th – Follow us on Twitter @PUBLIC_WIRE GNOLF- UP 100% PSSS – UP 89% TPIV – UP 44% SUB PENNY GAINERS – ELRA +337%, NNAN +283%, VTEQ +112%, SVFC +100% and MRIB +71% Stocks that took a tumble today- XTRN down 40% ALCSQ down 33% LEXG, GLFH both down 26%

    Read more
Public Wire Banner